Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
12/2000
12/28/2000WO2000053729A3 Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine
12/28/2000WO2000043495A3 33 human secreted proteins
12/28/2000WO2000043373A3 Kinase inhibitors
12/28/2000DE19929410A1 New octapepide compounds as alpha v beta 6 integrin inhibitors useful for treating and diagnosing heart disease, tumors, osteoporosis, fibrosis, inflammation, infection and psoriasis
12/28/2000CA2377530A1 Compositions and methods for the treatment or prevention of autoimmune disorders
12/28/2000CA2375493A1 Human transport proteins
12/28/2000CA2375407A1 Rna metabolism proteins
12/28/2000CA2375236A1 Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
12/28/2000CA2375211A1 Antiviral agents
12/28/2000CA2373921A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
12/27/2000EP1062210A1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
12/27/2000EP1061940A2 Use of follistatin to modulate gdf-8 and bmp-11
12/27/2000EP1061805A1 Regulation of endogenous gene expression in cells using zinc finger proteins
12/27/2000CN1059808C Powder for fracture and trauma
12/26/2000US6166206 Pyrrolo[3,4-D]Pyrimidinone derivatives and their use as medicaments
12/26/2000US6166193 Nucleotide sequence which encodes g-protein coupled receptor; for the treatment and prevention of bacterial, fungal, protozoan and viral infections; for use in gene therapy
12/26/2000US6166077 Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
12/26/2000US6166011 For treatment of disorders arising from neurodegenerative diseases or other disorders involving nerve damage
12/21/2000WO2000077225A1 A novel insulin signaling molecule
12/21/2000WO2000077206A2 The myostatin gene promoter and inhibition of activation thereof
12/21/2000WO2000077022A1 50 human secreted proteins
12/21/2000WO2000076988A1 Rhodanine derivatives and their use in inhibiting and imaging amyloids
12/21/2000WO2000076553A1 Use of viral vectors and charged molecules for gene therapy
12/21/2000WO2000076531A1 47 human secreted proteins
12/21/2000WO2000076530A1 49 human secreted proteins
12/21/2000WO2000076503A1 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
12/21/2000WO2000076452A2 Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative
12/21/2000WO2000076451A2 Pharmaceutical composition comprising no or at least a no donor compound inducing no formation in cells
12/21/2000WO2000047762A3 Enriched central nervous system cell populations
12/21/2000WO2000047580A3 Phenyl urea and phenyl thiourea derivatives
12/21/2000WO2000045791A3 Method for controlling liposome size
12/21/2000WO2000044361A3 Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders
12/21/2000WO2000038660A3 Use of bisphosphonates for the prevention and treatment of infectious processes
12/21/2000EP1144671A3 Enriched central nervous system cell populations
12/21/2000DE19925739A1 Therapeutikum mit einem Botulinum-Neurotoxin Agent with a botulinum neurotoxin
12/21/2000CA2391364A1 47 human secreted proteins
12/21/2000CA2390946A1 49 human secreted proteins
12/21/2000CA2382748A1 50 human secreted proteins
12/21/2000CA2379048A1 Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative
12/21/2000CA2377153A1 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
12/21/2000CA2376956A1 Charged compounds facilitate viral transduction of cells
12/21/2000CA2376302A1 Pharmaceutical composition comprising no or at least a no donor compound or another compound capable of releasing or inducing no fromation in cells
12/21/2000CA2370316A1 Rhodanine derivatives and their use in inhibiting and imaging amyloids
12/20/2000EP1060188A1 Cholenic acid amides and pharmaceutical compositions thereof
12/20/2000EP1060181A1 Substituted pyrrolobenzimidazoles for treating inflammatory diseases
12/20/2000EP1060178A1 Heterocyclic compounds as inhibitors of rotamase enzymes
12/20/2000EP0938309A4 Methods for in vivo reduction of iron levels and compositions useful therefor
12/20/2000CN1277613A Poly (ADP-ribose) polymerase ('PARP') inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
12/20/2000CN1277604A Heteraryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
12/20/2000CN1059580C Sikang yangsheng health-care tablet
12/19/2000US6162790 Oligopeptides
12/19/2000CA2189527C Novel elastase inhibitors
12/14/2000WO2000075365A2 Compounds and methods to enhance raav transduction
12/14/2000WO2000075348A1 Recombinant anti-cd40 antibody and uses thereof
12/14/2000WO2000075318A1 Phospholipid transfer protein
12/14/2000WO2000075309A1 Spliceosome protein and its use
12/14/2000WO2000075187A1 An integrin heterodimer and an alpha subunit thereof
12/14/2000WO2000075176A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf)
12/14/2000WO2000075163A1 Angiogenic proteins and uses thereof
12/14/2000WO2000075144A2 Peroxynitrite decomposition catalysts and methods of use thereof
12/14/2000WO2000075139A2 Benzothiazinone and benzoxazinone compounds
12/14/2000WO2000075131A1 Substituted pyrazole compounds
12/14/2000WO2000075109A1 Ethanesulfonyl-piperidine derivatives
12/14/2000WO2000075107A2 Bradykinin receptor antagonists
12/14/2000WO2000074724A2 Conjugates comprising cytokines and nucleic acids for treating proliferating cells
12/14/2000WO2000074722A2 Modification of biological elements
12/14/2000WO2000074718A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/14/2000WO2000074717A1 NOVEL Ig FRACTIONS HAVING AN IMMUNOMODULATORY ACTIVITY
12/14/2000WO2000074706A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
12/14/2000WO2000074703A2 Therapeutic agent comprising a botulinum neurotoxin
12/14/2000WO2000074584A1 Devices and methods for treating tissue
12/14/2000CA2376729A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf)
12/14/2000CA2376400A1 Compounds and methods to enhance raav transduction
12/14/2000CA2376335A1 Novel ig fractions having an immunomodulatory activity
12/14/2000CA2376210A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
12/14/2000CA2376055A1 Spliceosomal protein and its use
12/14/2000CA2376018A1 Angiogenic proteins and uses thereof
12/14/2000CA2375912A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/14/2000CA2375876A1 An integrin heterodimer and an alpha subunit thereof
12/14/2000CA2375734A1 Benzothiazinone and benzoxazinone compounds
12/14/2000CA2374558A1 Phospholipid transfer protein
12/14/2000CA2373336A1 Peroxynitrite decomposition catalysts and methods of use thereof
12/13/2000EP1059088A1 New Ig-fractions with immunomodulation activity
12/13/2000EP1058730A1 Human synapse related glycoproteins (hsrp)
12/13/2000EP1058726A2 Novel mechanically sensitive mammal potassium channel family activated by polyunsaturated fatty acids and their use particularly for screening medicines
12/13/2000EP1058698A1 Preparation for prevention and healing of inflammation affections
12/12/2000US6159998 Administered as vasodilators, analgesics, anesthetics, sedatives, and anitspasmodic agents
12/12/2000US6159943 Use of ribose to prevent cramping and soreness in muscles
12/12/2000US6159732 Nucleic acid encoding mammalian Ubr1
12/07/2000WO2000073450A2 Cytoskeleton-associated proteins
12/07/2000WO2000073334A2 Human sorting nexins
12/07/2000WO2000073324A2 Modulation of gene expression in gastrointestinal inflammation
12/07/2000WO2000072881A1 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
12/07/2000WO2000072861A1 Pharmaceutical preparations of bioactive substances extracted from natural sources
12/07/2000WO2000072832A2 Novel use of 1-[4-(cyanoindol-3yl)butyl]-4-(carbamoyl-benzofuran-5yl)-piperazine and its physiologically acceptable salts
12/07/2000WO2000063402A8 Cassette regulating the expression of a heterologous nucleic acid in a eucaryotic cell, especially a muscle cell
12/07/2000WO2000045801A3 Use of a nitrate vasodilator alone or in combination with capsaicin for the treatment of pain
12/07/2000CA2694866A1 Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
12/07/2000CA2414094A1 Pharmaceutical preparations of bioactive substances extracted from natural sources
12/07/2000CA2375855A1 Modulation of gene expression in gastrointestinal inflammation
1 ... 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 ... 233